Welcome to our dedicated page for Cytosorbents SEC filings (Ticker: CTSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytosorbents Corporation filings document the company's public reporting as a Nasdaq-listed medical technology issuer with common stock registered under Section 12(b). Recent Form 8-K filings furnish results of operations and financial condition, press release exhibits, Regulation FD disclosures, and other event reports tied to the company's blood purification business.
The filing record also documents regulatory disclosure categories for DrugSorb®-ATR, including FDA and Health Canada communications, De Novo market authorization matters, and related supervisory review or reconsideration processes. Other filings address Nasdaq continued-listing compliance under minimum bid price rules, credit-facility and balance-sheet disclosures reported with earnings releases, and the exhibits that support material corporate updates.
CytoSorbents Corporation reported that it received a notice from Nasdaq stating it is not in compliance with Nasdaq Listing Rule 5550(b)(2), which requires a minimum Market Value of Listed Securities of $35 million for the Nasdaq Capital Market.
The company has 180 calendar days, until December 28, 2026, to regain compliance by having its market value meet or exceed $35 million for at least 10 consecutive business days, subject to potential Nasdaq discretion. The notice does not immediately delist the stock, but failure to regain compliance could lead to a delisting determination, which the company could then appeal.
CytoSorbents is evaluating potential actions to regain compliance, including actively monitoring its market value and potentially increasing stockholders’ equity to at least $2.5 million as another route to satisfy Nasdaq’s continued listing standards. The filing notes there is no assurance the company will succeed in maintaining its Nasdaq Capital Market listing.
CytoSorbents Corporation is asking stockholders to approve five proposals at its 2026 virtual annual meeting. The meeting will be held online on August 13, 2026, for holders of common stock of record as of June 15, 2026, when 62,842,748 shares were outstanding.
Stockholders will vote on re-electing five directors, a non-binding advisory Say‑on‑Pay proposal on executive compensation, ratifying WithumSmith+Brown, PC as auditor for 2026, and a reverse stock split at a Board‑selected ratio between 1‑for‑5 and 1‑for‑20. The reverse split is intended to help restore compliance with Nasdaq’s $1.00 minimum bid price after a deficiency notice and an extension to September 28, 2026. An adjournment proposal would allow the meeting to be postponed if additional votes are needed.
CytoSorbents Corporation furnished an investor presentation describing its blood purification business and regulatory plans for its DrugSorb-ATR device. The company has scheduled two FDA pre-submission meetings in August 2026 to discuss ticagrelor removal in cardiac surgery and a potential expanded indication for DOAC removal.
The presentation highlights 2025 sales of $37 with 71% gross margins and a high-margin "razorblade" consumables model across more than 70 countries and 300,000+ CytoSorb treatments. In Q1 2026, sales were $8, up 2% year over year, with product gross margins of 69% as the company deliberately slowed production to reduce inventory.
Management reports negative free cash flow improving, ending Q1 2026 with $6.4 million in cash, cash equivalents and restricted cash and a cash burn of $1.1 million in the quarter. The company aims for operating cash flow breakeven in the second half of 2026 and targets profitability in 2027 while pursuing De Novo submissions for DrugSorb-ATR in North America.
Cytosorbents Corp Chief Financial Officer Peter J. Mariani reported an open-market purchase of 100,000 shares of Common Stock at a weighted average price of $0.44 per share on June 15, 2026. Following this transaction, he directly holds 638,113 shares, which include a mix of common shares and restricted stock units that vest over time or upon a defined change in control, subject to his continued service.
Cytosorbents Corp CEO Phillip P. Chan reported open-market purchases of company common stock. On June 12, 2026, he bought 251,136 shares at a weighted average price of $0.40 per share. On June 15, 2026, he bought another 10,333 shares at a weighted average price of $0.43 per share.
Following these transactions, Chan directly holds 1,744,432 shares reported as common stock, a figure that includes several grants of restricted stock units that vest upon a Change In Control or over time, plus 1,422,832 shares of currently owned common stock.
CytoSorbents Corporation is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders to be held on August 13, 2026 at 10:00 a.m. Eastern Time. The Board asks holders to vote on five proposals: election of five directors, a non-binding advisory vote on executive compensation, ratification of WithumSmith+Brown, PC as auditor, a reverse stock split authorizing a ratio between 1-for-5 and 1-for-20, and an adjournment proposal.
The proxy materials and the Annual Report for the fiscal year ended December 31, 2025 are available at www.proxyvote.com. The reverse split is presented to help the Company meet Nasdaq’s minimum bid price requirement of $1.00; Nasdaq granted an extension until September 28, 2026 after a notice dated October 2, 2025. The Certificate of Incorporation authorizes 105,000,000 total shares (100,000,000 common; 5,000,000 preferred). Voting mechanics, broker voting rules, fractional-share treatment (round up), and certain tax and accounting consequences of the reverse split are described in the Proxy Statement.
CytoSorbents Corporation reported Q1 2026 results showing modest revenue growth but a larger loss and tight liquidity. Revenue was $8.9 million, up slightly from $8.7 million a year ago, with gross margin at 69%. Operating expenses fell to $9.2 million from $10.1 million, mainly from lower R&D and cost-cutting, reducing the operating loss to $3.0 million from $3.9 million.
However, a $1.2 million foreign currency loss and higher interest expense widened net loss to $5.1 million, or $0.08 per share, versus $1.5 million, or $0.02 per share, in Q1 2025. Cash, cash equivalents and restricted cash totaled $6.3 million as of March 31, 2026, including $4.8 million of unrestricted cash, against $18.4 million of Avenue Capital debt maturing in 2027.
The company discloses that these cash levels, together with ongoing cash use in operations, raise “substantial doubt” about its ability to continue as a going concern over the next 12 months. Management is pursuing a Strategic Workforce and Cost Reduction Plan, has cut headcount by about 10%, and is seeking additional financing while continuing to work toward FDA De Novo approval of its DrugSorb-ATR device.
CytoSorbents Corporation reported first quarter 2026 revenue of $8.9 million, roughly flat year over year, with 13% growth in direct markets outside Germany and slightly lower sales in Germany on a leaner sales team. Distributor sales were unchanged as delayed orders of about $0.5 million in parts of the Middle East offset progress elsewhere.
Gross margin was 69%, down slightly as the company deliberately reduced production to lower inventory and improve working capital. A late-2025 cost reduction that cut headcount by about 10% helped trim operating expenses, though net loss widened to $5.1 million, or $0.08 per share, versus a $1.5 million loss a year earlier. Adjusted EBITDA improved modestly to a loss of $2.2 million.
The company outlined its U.S. regulatory strategy for the DrugSorb-ATR device. After an FDA appeal maintained a prior denial but raised no safety concerns, CytoSorbents plans a new De Novo application for use with Brilinta, targeting submission in late 2026 or early 2027, and is preparing a separate pre-submission for a potential DOAC indication. Management reiterated its goal of reaching operating cash flow breakeven in the second half of 2026 while navigating temporary geopolitical headwinds and expanding its commercial footprint.
CytoSorbents Corporation filed an amended annual report on Form 10‑K/A to add Part III information and update officer certifications, without changing prior financial statements. The amendment provides detailed disclosures on board composition, committee structures, director independence, executive and director compensation, equity plans, and security ownership.
As of June 30, 2025, non‑affiliate common stock had an aggregate market value of about $60.6 million, and approximately 62.7 million shares of common stock were outstanding as of March 20, 2026. The filing also confirms there were no related party transactions above required disclosure thresholds in 2025 and 2024 and outlines auditor fees and pre‑approval policies.